What Growth Rate Is Fast for a Renal Angiomyolipoma?

A renal angiomyolipoma (AML) is typically a benign kidney tumor made up of varying amounts of blood vessels, smooth muscle, and fat. While “benign” means it is not cancer, it does not mean the tumor can never cause problems, such as bleeding. Most renal AMLs grow very slowly, and many do not show measurable growth at all.

While there is no single universal rule for every patient, a growth rate of more than 0.25 cm (2.5 mm) per year is frequently used in medical studies as a warning threshold or risk marker that may prompt doctors to consider closer monitoring or discuss treatment options ^[1]. However, exceeding this threshold is not an automatic mandate for treatment. Treatment decisions are highly individualized and based on a combination of the growth trend, overall size, symptoms, and the presence of blood vessel abnormalities ^[1][2].

Sporadic vs. TSC-Associated Growth Rates

How fast an AML grows depends heavily on the specific patient population and whether the tumor is sporadic (occurring randomly) or associated with Tuberous Sclerosis Complex (TSC), a genetic condition.

• Sporadic AMLs: These are the most common type and usually grow very slowly. In one large study of untreated AMLs, more than 92% of the tumors showed no measurable growth over a median follow-up of 43 months ^[3]. When looking specifically at small sporadic tumors (under 2 cm) detected on ultrasound, average growth rates are often reported in fractions of a millimeter (e.g., 0.13 to 0.24 mm/year) ^[4][5]. In a different surveillance cohort that included larger or more closely monitored tumors, the mean growth rate for sporadic AMLs was slightly higher at 2.7 mm/year ^[6].
• TSC-Associated AMLs: Tumors linked to TSC tend to develop at a younger age, are often present in both kidneys, and generally grow faster than sporadic AMLs ^[2][7]. In the same surveillance study mentioned above, TSC-associated AMLs grew at an average rate of 5.4 mm/year ^[6]. Patients with features of TSC should often ask about a genetics referral.

Note: Group averages from studies do not predict the exact growth rate of an individual tumor.

The 0.25 cm Threshold and Measurement Variability

If a new scan shows your tumor is 2 mm larger than it was last year, it does not automatically mean the tumor is actively growing at a dangerous rate. A small change in size can often be chalked up to measurement variability. This happens because:

• Different imaging machines (ultrasound, CT, or MRI) measure tissues slightly differently ^[8].
• The angle or “slice” of the image can vary from scan to scan.
• Different radiologists may measure the tumor at slightly different points.

Because of this variability, doctors usually want to establish a confirmed growth trend over multiple scans using the same imaging method rather than reacting to a single small change on one report ^[8].

Tracking Your Scans

To help understand your own growth trend, it can be helpful to keep a personal record of your scan results. You can use a simple table like this:

When Does Growth Require Treatment?

A fast-growing tumor is just one piece of the puzzle. Historically, a tumor reaching 4 cm in size was considered an automatic trigger for treatment, but modern guidelines emphasize that size alone does not mandate early intervention for everyone ^[3][9]. Instead, doctors look at the complete risk profile.

Factors that increase the need to discuss treatment include:

• Aneurysms: The formation of intralesional aneurysms (weak, bulging blood vessels inside the tumor). Aneurysms larger than 5 mm are strongly associated with a higher risk of the tumor bleeding or rupturing ^[1][10].
• Pregnancy: Hormonal and physical changes during pregnancy can increase the risk of tumor growth and rupture. People of childbearing age with fast-growing or large AMLs should have individualized discussions with their doctor about pregnancy planning and potential preventive treatment before conception ^[1][11].
• Symptoms: Clinical symptoms such as flank pain or blood in the urine (hematuria) require medical evaluation and may indicate a need for treatment ^[1][2].

Emergency Warning: Sudden, severe flank, back, or abdominal pain, fainting or marked dizziness, weakness, rapid heartbeat, or substantial visible blood in the urine can be signs of internal bleeding. If you experience these symptoms, seek emergency medical evaluation immediately.

For many patients without these high-risk features, active surveillance (regular imaging and check-ups) is a reasonable and appropriate approach ^[3][9]. The exact surveillance schedule is individualized based on tumor size, TSC status, kidney function, and patient preference.